Day One Biopharmaceuticals, Inc. (DAWN)
- Previous Close
16.41 - Open
16.55 - Bid 16.36 x 1000
- Ask 16.43 x 700
- Day's Range
16.26 - 16.94 - 52 Week Range
9.67 - 18.07 - Volume
600,734 - Avg. Volume
1,096,324 - Market Cap (intraday)
1.431B - Beta (5Y Monthly) -1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-2.50 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.38
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
dayonebio.comRecent News: DAWN
Performance Overview: DAWN
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DAWN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DAWN
Valuation Measures
Market Cap
1.43B
Enterprise Value
1.12B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.83
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.93
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.67%
Return on Equity (ttm)
-69.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-208.94M
Diluted EPS (ttm)
-2.50
Balance Sheet and Cash Flow
Total Cash (mrq)
317.94M
Total Debt/Equity (mrq)
0.10%
Levered Free Cash Flow (ttm)
-95.76M
Research Analysis: DAWN
Company Insights: DAWN
DAWN does not have Company Insights